Video

Dr. Peter Marks on the Adoption of Novel Precision Analytics

The FDA is very committed to improving the quality, consistency, and yields of advanced therapy products through the adoption of novel precision analytics. In this segment, Dr. Peter Marks shares advice for developers that might be worried that the Agency will not accept changes in their process that include a new analytical method.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

Thermo Fisher Scientific Bioproduction